الصفحة الرئيسية>>Signaling Pathways>> Angiogenesis>> Integrin>>Fradafiban hydrochloride

Fradafiban hydrochloride

رقم الكتالوجGC70223

Fradafiban hydrochloride هو مضاد بروتين سكري صفيحي غير ببتيدي IIb/IIIa، والذي يرتبط بمركب الصفيحة البشرية GP IIb/IIIa بقيمة Kd تبلغ 148 نانومتر.

Products are for research use only. Not for human use. We do not sell to patients.

Fradafiban hydrochloride التركيب الكيميائي

الحجم السعر المخزون الكميّة
1 mg
765٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.

Fradafiban hydrochloride is a nonpeptide mimetic of the arginine-glycine-aspartic acid recognition sequence. Fradafiban hydrochloride binds with high affinity and selectivity to the human platelet GP IIb/IIIa complex and potently inhibits human platelet aggregation in vitro. Fradafiban hydrochloride reversibly binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM[1].

Fradafiban hydrochloride has only very limited oral activity probably due to its high polarity and thus poor absorption after oral ingestion[1].

References:
[1]. Müller TH, et al. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997 Aug 19;96(4):1130-8.

مراجعات

Review for Fradafiban hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fradafiban hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.